Últimas noticias sobre MediciNova (NASDAQ:MNOV) Bolsa

MediciNova

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

MediciNova Inc

<h3>Gainers</h3>
<ul>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares increased by 51.8% to $0.91 during Friday's regular session. The market value of their outstanding shares is at $9.2 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 22.41% to $0.3. The market value of their outstanding shares is at $7.0 million. </li>
<li>Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) stock rose 21.29% to $1.88. The company's market cap stands at $512.3 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) stock rose 18.15% to $0.47. The company's market cap stands at $1.5 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 17.99% to $1.64. The market value of their outstanding shares is at $3.0 million. </li>
<li>Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) stock increased by 16.08% to $3.68. The company's market cap stands at $97.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) shares fell 13.4% to $11.47 during Friday's regular session. The market value of their outstanding shares is at $773.3 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 13.37% to $0.51. The company's market cap stands at $2.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 10.15% to $6.2. The market value of their outstanding shares is at $80.6 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 9.95% to $3.53. The company's market cap stands at $3.2 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) shares declined by 9.69% to $6.25. The company's market cap stands at $113.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 9.37% to $1.78. The market value of their outstanding shares is at $87.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CATX

CBUS

ENTO

GNTA

HSCS

MNOV

NIVF

NUWE

PACB

PTIX

12 Health Care Stocks Moving In Friday's Intraday Session

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) has awarded $22 million for an intermediate size Expanded Access Protocol (EAP) to evaluate the efficacy of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)1,2. In collaboration with an academic group, MediciNova will provide investigational drug MN-166 (ibudilast), regulatory support, and safety monitoring support. &nbsp;
The NIH grant is supported by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS) signed into law by President Biden. Expanded Access, also referred to as Compassionate Use, is an FDA-regulated pathway that allows individuals with a serious and life-threatening disease to access an investigational drug that is not yet approved by the FDA. This EAP trial will allow individuals with ALS who are not eligible to participate in the COMBAT-ALS trial to receive treatment with MN-166. The EAP will evaluate neurofilament light, a biomarker for neuron damage, and clinical data in two hundred (200) ALS patients treated with MN-166.

Biotech

News

Contracts

General

MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis

Reported Earlier, MediciNova's MN-166 COMBAT-ALS Trial Abstract Accepted For Poster Presentation At 35th ALS/MND Symposium

Reported Earlier, MediciNova's MN-166 (Ibudilast) ALS Clinical Trial Abstract Accepted For Presentation At 2024 NEALS Annual Meeting

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM).
Nikola shares dipped 10.4% to $7.28 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) shares jumped 103% to $0.6719. Sify becomes first in India to achieve NVIDIA DGX-ready data center certification for liquid cooling to enable breakthrough AI performance.</li>
<li>BranchOut Food Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOF#NASDAQ">BOF</a>) gained 85% to $3.70.</li>
<li>SPAR Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) surged 65% to $2.3950 after the company announced it entered into a definitive agreement to be acquired by Highwire Capital for $2.50 per share.</li>
<li>Asset Entities Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) rose 62.7% to $2.31.</li>
<li>Conifer Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) shares jumped 56% to $1.0250 after the company announced that it completed the sale of its insurance agency operations for a $45 million consideration. The company appointed Brian Roney as CEO.</li>
<li>Auddia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) gained 44.6% to $1.25 after the company announced it recently launched both Apple CarPlay and Android Auto interfaces for its faidr mobile application.</li>
<li>Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) surged 43.5% to $115.92 after the company announced it selected VAX-31 to advance to an adult Phase 3 program following topline results from its Phase 1/2 study.</li>
<li>Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) gained 28.8% to $21.69.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) rose 21.8% to $6.57 after the company received a favorable legal ruling from the U.S. ITC in its patent infringement complaint against Voltage, LLC and a related foreign entity.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) jumped 17.5% to $6.55 after the company announced it dosed 5 new patients in its ACHIEVE Phase 2b trial.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 16.5% to $1.27.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) gained 16% to $1.4150 after the company appointed former Stellantis executive Jean-Francois Mady as its new CFO.</li>
<li>Chemomab Therapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) surged 15.8% to $2.34.</li>
<li>MediciNova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) gained 15.3% to $1.73. MediciNova recently announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 for post-COVID conditions.</li>
<li>GD Culture Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDC#NASDAQ">GDC</a>) rose 12.8% to $6.86.</li>
<li>Big Tree Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSY#NASDAQ">DSY</a>) jumped 12.6% to $5.99.</li>
<li>Avalo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) gained 11.4% to $8.29.</li>
<li>Motorsport Games Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) rose 11.3% to $1.3250.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) gained 10.7% to $12.57 after Raymond James upgraded the stock from Market Perform to Outperform and announced a $17 price target.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 9.4% to $17.91 after Morgan Stanley upgraded the stock from Equal-Weight to Overweight.</li>
<li>Intchains Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) climbed 8.1% to $7.89.</li>
<li>Keros Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) gained 8.1% to $49.04 after the company announced an update on enrollment in the Phase 2 TROPOS trial.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 4.5% to $12.94. Friday, the FDA granted Emergency Use Authorization to Novavax Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) for active immunization to prevent COVID-19 in individuals aged 12 and older.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares dipped 42.2% to $4.68.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) fell 31.7% to $31.47. The company announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 31.3% to $1.75 after jumping 60% on Friday.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) dipped 29.3% to $1.06 after the company announced the IDMC observed no new safety signals in the Phase 3 trial of IO102-IO103. Also, Morgan Stanley maintained an Overweight rating on the stock but lowered its price target from $7 to $4.</li>
<li>Brenmiller Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNRG#NASDAQ">BNRG</a>) fell 25.8% to $1.1499. Brenmiller recently reported a year-over-year increase in H1 EPS results. Also, the company announced a projected pipeline valued up to $500 million.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) dipped 22.8% to $1.13.</li>
<li>Four Seasons Education (Cayman) Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FEDU#NYSE">FEDU</a>) fell 21.8% to $13.30.</li>
<li>Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>) declined 21.6% to $3.55.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 18.8% to $1.5506.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) dipped 18.6% to $3.99.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) fell 16.1% to $8.49.</li>
<li>LightInTheBox Holding Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NASDAQ">LITB</a>) declined 14.3% to $0.4455.</li>
<li>NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) fell 12.7% to $16.97 as the company announced planned CEO transition.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) fell 10.8% to $4.2350.</li>
<li>Nova Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) declined 9.6% to $202.16.</li>
<li>Tidewater Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) fell 8.5% to $81.15.</li>
<li>Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) fell 8.5% to $109.35.</li>
<li>The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) fell 8.3% to $159.27 ahead of the September 12 expiration of the company&#8217;s contract with the International Association of Machinists, which could lead to a potential strike. Additionally, Wells Fargo downgraded the stock from Equal-Weight to Underweight.</li>
<li>Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) dipped 8% to $75.43.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) fell 7.2% to $70.73.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) declined 7% to $20.52.</li>
<li>Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) fell 6.2% to $185.01.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/40683473/top-3-tech-and-telecom-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Tech And Telecom Stocks Which Could Rescue Your Portfolio This Month</a></li>
</ul>

Intraday Update

Markets

AAOI

AGMH

AIXI

AMAT

APDN

ASST

ATPC

AUUD

AVTX

BNRG

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNFR

FEDU

GERN

INTC

IOBT

KROS

LITB

MRVL

MSGM

NVAX

NVCR

NVMI

PCVX

PSNY

QNTM

RXRX

SGRP

SHLS

SIFY

SLXN

STRL

TCBP

WINT

Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

WIIM

MediciNova shares are trading higher after the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers MN-166 for post-COVID conditions.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the&nbsp;U.S.&nbsp;Patent and&nbsp;Trademark Office&nbsp;for a pending patent application, which covers MN-166 (ibudilast) for post-COVID conditions. The Method of Use patent covers administering a therapeutically effective doses of ibudilast (or a pharmaceutically acceptable salt thereof) to alleviate a range of post-COVID conditions including anxiety, fatigue, depression, shortness of breath, post-traumatic stress disorder, chest tightness, palpitations, smell or taste dysfunction, sleep difficulties, hair loss, and rash.

Reported Earlier, MediciNova Receives U.S. Patent Allowance For MN-166, Ensuring Broad Protection For Post-COVID Treatment Through 2042

Health Care

MediciNova Has Received A Notice Of Allowance From The US Patent And Trademark Office For A Pending Patent Application Covering MN-166 (Ibudilast) For The Prevention Of Metastasis In Various Cancers

The highlights of presentation are as follows:
The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.
The combination of Temozolomide (TMZ) and MN-166 was safe and well tolerated. No unexpected adverse effects were observed in both new GBM and recurrent GBM patients. Most reported adverse events were Lymphopenia, Leukopenia, Thrombocytopenia and Neutropenia.
<div>Preclinical data has shown improved survival with the combination of Ibudilast and PD-1 or PD-L1 antibody therapy compared to treatment with ibudilast alone or PD-1/PD-L1 antibody alone, suggesting a potential promising therapeutic benefit of this combination.</div>

MediciNova Presents New Data And Results Of Phase 1b/2a Clinical Trial Of MN-166 At ASCO Meeting

MediciNova Receives Notice Of Allowance From US PTO For Pending Patent Application Which Covers MN-166 (Ibudilast) For Prevention Of Metastasis Of Eye Cancer

MediciNova Receives Notice Of Allowance For New Patent Covering MN-166 (Ibudilast) For Chlorine-induced Acute Respiratory Distress Syndrome, Once Issued, This Patent Is Expected To Expire No Earlier Than January 2042

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. </li>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. </li>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock increased by 6.79% to $1.1. The market value of their outstanding shares is at $248.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock declined by 10.3% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $81.1 million. </li>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 4.9% to $0.02. The market value of their outstanding shares is at $1.1 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock fell 4.82% to $1.78. The market value of their outstanding shares is at $322.6 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares declined by 4.7% to $1.42. The company's market cap stands at $69.6 million. </li>
<li>Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) stock fell 4.63% to $2.06. The market value of their outstanding shares is at $140.4 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) stock declined by 4.33% to $12.03. The market value of their outstanding shares is at $623.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ATNF

CERS

ELTX

ETAO

GOSS

LGVN

SINT

STOK

12 Health Care Stocks Moving In Friday's After-Market Session

Abstract Number:&nbsp;2106
Title:&nbsp; Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)
Session&nbsp;Title: Rapid Oral Abstract &ndash; Central Nervous System Tumors
Session Date:&nbsp;June 2, 2024
Session Time:&nbsp;11:30 AM &ndash; 1:00 PM

Reported Earlier, Medicinova Announces Abstract Regarding Results Of A Clinical Trial Of MN-166 In Glioblastoma Accepted For Presentation At The 2024 ASCO

<h3>Gainers</h3>
<ul>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 67.2% to $3.77 during Wednesday's pre-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares rose 24.34% to $3.78. The company's market cap stands at $31.9 million. </li>
<li>NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) stock rose 17.9% to $15.41. The company's market cap stands at $1.6 billion. </li>
<li>Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) shares increased by 14.93% to $0.53. The market value of their outstanding shares is at $18.5 million. As per the news, the Q4 earnings report came out today. </li>
<li>Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) shares moved upwards by 11.11% to $3.2. The market value of their outstanding shares is at $700.9 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares rose 10.29% to $1.5. The company's market cap stands at $73.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 20.6% to $0.3 during Wednesday's pre-market session. The company's market cap stands at $23.7 million. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) stock fell 15.67% to $0.63. The market value of their outstanding shares is at $6.3 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares declined by 14.76% to $3.35. The company's market cap stands at $339.9 million. </li>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) stock declined by 12.72% to $7.55. The market value of their outstanding shares is at $405.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock decreased by 12.68% to $0.53. The company's market cap stands at $23.0 million. </li>
<li>PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) shares decreased by 12.28% to $3.93. The company's market cap stands at $122.2 million. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

LIXT

MESO

NTRB

NUVB

OPGN

PDSB

SSKN

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of MariaDB plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrdb#NYSE">MRDB</a>) rose sharply in today&rsquo;s pre-market trading after Progress Software (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prgs#NASDAQ">PRGS</a>) announced that it is possibly considering an offer for the company.
MariaDB shares jumped 100.4% to $0.4530 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Destiny Tech100 Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) rose 52.9% to $13.76 in pre-market trading after gaining 9% on Tuesday.</li>
<li>PaySign, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pays#NASDAQ">PAYS</a>) gained 25.2% to $4.23 in pre-market trading after the company announced better-than-expected fourth-quarter results.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) gained 19.1% to $1.69 in pre-market trading.</li>
<li>The ONE Group Hospitality, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stks#NASDAQ">STKS</a>) shares rose 13.2% to $4.54 in pre-market trading after the company announced that it will acquire Safflower Holdings.</li>
<li>nCino, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncno#NASDAQ">NCNO</a>) gained 11.7% to $33.72 in pre-market trading as the company reported better-than-expected fourth-quarter results and issued FY25 adjusted earnings guidance above estimates..</li>
<li>Nuvation Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuvb#NASDAQ">NUVB</a>) shares rose 11.5% to $3.21 in pre-market trading. Nuvation Bio shares gained 28% on Tuesday after BTIG upgraded the stock from Neutral to Buy.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/djt#NASDAQ">DJT</a>) gained 11.5% to $64.70 in pre-market trading after jumping 16% on Tuesday.</li>
<li>MediciNova, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnov#NASDAQ">MNOV</a>) climbed 10.2% to $1.50 in pre-market trading. MediciNova received a Notice of Allowance from Japan Patent Office for MN-166 in macular injury treatment.</li>
<li><a href="https://www.benzinga.com/money/robinhood-alternatives/">Robinhood</a> Markets, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hood#NASDAQ">HOOD</a>) gained 6.3% to $20.50 in pre-market trading. Robinhood launched its Gold Card, offering a 1% boost on Gold deposits and a redesigned app. The announcement was made at its first-ever keynote event.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Direct Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/drct#NASDAQ">DRCT</a>) dipped 39.8% to $15.95 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Velo3D, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vld#NYSE">VLD</a>) declined 34.1% to $0.3820 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) fell 30.9% to $0.0760 pre-market trading after dipping over 6% on Tuesday. The Nasdaq recently determined that the company is no longer suitable for listing and its stock will be suspended on March 28.</li>
<li>LuxUrban Hotels Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/luxh#NASDAQ">LUXH</a>) fell 20.5% to $1.70 pre-market trading after the company issued preliminary unaudited 2023 fourth quarter and full year financial results.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) shares fell 14.9% to $13.19 in pre-market trading as the company posted weaker-than-expected results for its fourth quarter on Tuesday.</li>
<li>Akili, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akli#NASDAQ">AKLI</a>) shares tumbled 13.6% to $0.3289 in pre-market trading. The company received a notice of allowance for U.S. Patent Application 17/890,478 titled Cognitive Platform For Deriving Effort Metric For Optimizing Cognitive Treatment (Using Data Computed With Artificial Neural Network Or Deep Learning Techniques)</li>
<li>Forge Global Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/frge#NYSE">FRGE</a>) fell 12.4% to $2.32 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) shares dropped 12.1% to $3.45 in pre-market trading. Mesoblast shares jumped over 78% on Tuesday after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) fell 10.4% to $1.03 in pre-market trading.</li>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) fell 7.7% to $0.72 in pre-market trading after gaining 7% on Tuesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37927495/jim-cramer-says-dont-sell-this-beauty-brand-believes-kkr-and-blackstone-can-make-more-mo"> Jim Cramer Says Don&#39;t Sell This Beauty Brand, Believes KKR And Blackstone &#39;Can Make More Money&#39;</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Trading Ideas

ABTS

DRCT

DXYZ

FRGE

HKIT

HOOD

JOAN

LUXH

MIRA

MRDB

NCNO

PAYS

PRGS

STKS

Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket

Once issued, this patent is expected to expire no earlier than&nbsp;October 2039. &nbsp;The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.&nbsp;

Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment

&nbsp;MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled&nbsp;&quot;STUDY PROTOCOL TO EVALUATE MN-001&#39;S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)&quot;&nbsp;and &quot;MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX&quot; have been accepted and selected for poster presentation at the 92nd&nbsp;European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.

Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress

MediciNova Announces New Data and Results of MN-166 (Ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented At The Annual Meeting of the Society of Toxicology

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) stock rose 120.5% to $33.3 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares increased by 97.24% to $75.9. The market value of their outstanding shares is at $7.6 billion. </li>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock rose 22.2% to $95.0. The company's market cap stands at $3.1 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) shares rose 21.24% to $3.88. The market value of their outstanding shares is at $270.9 million. </li>
<li>Ligand Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGND#NASDAQ">LGND</a>) shares moved upwards by 20.93% to $90.0. The company's market cap stands at $1.5 billion. The company's, Q4 earnings came out today. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) shares rose 19.5% to $12.25. The company's market cap stands at $2.5 billion. As per the press release, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares decreased by 22.9% to $0.33 during Tuesday's pre-market session. The company's market cap stands at $28.0 million. </li>
<li>Veradigm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDRX#NASDAQ">MDRX</a>) shares decreased by 22.03% to $6.48. The market value of their outstanding shares is at $708.0 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares decreased by 18.32% to $13.07. The market value of their outstanding shares is at $53.1 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares fell 14.79% to $1.21. The market value of their outstanding shares is at $31.8 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) shares fell 11.54% to $1.15. The company's market cap stands at $56.4 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock fell 10.23% to $0.43. The market value of their outstanding shares is at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BEAT

BSGM

CDXS

DTIL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

JANX

LGND

MDRX

NRXP

TMDX

VKTX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 25.2% to $2.73 during Friday's pre-market session. The company's market cap stands at $1.5 million. </li>
<li>MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) stock increased by 17.77% to $1.59. The market value of their outstanding shares is at $77.9 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares moved upwards by 14.5% to $143.0. The market value of their outstanding shares is at $13.3 billion. </li>
<li>Ikena Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) shares rose 12.32% to $1.64. The company's market cap stands at $79.1 million. </li>
<li>Sientra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIEN#NASDAQ">SIEN</a>) stock increased by 11.4% to $0.38. The company's market cap stands at $4.5 million. </li>
<li>Artivion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AORT#NYSE">AORT</a>) stock increased by 10.86% to $20.0. The market value of their outstanding shares is at $820.9 million. As per the news, the Q4 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) shares decreased by 8.6% to $3.6 during Friday's pre-market session. The company's market cap stands at $185.9 million. </li>
<li>T2 Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) shares declined by 7.67% to $5.9. The company's market cap stands at $23.8 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 7.66% to $2.51. The market value of their outstanding shares is at $10.8 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares fell 7.41% to $2.5. The market value of their outstanding shares is at $10.8 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock decreased by 7.31% to $1.65. The company's market cap stands at $34.8 million. </li>
<li>AMN Healthcare Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMN#NYSE">AMN</a>) shares fell 7.26% to $72.0. The market value of their outstanding shares is at $2.7 billion. The company's, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AORT

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

HCTI

HEPA

IKNA

SIEN

SRPT

SXTC

TTOO

12 Health Care Stocks Moving In Friday's Pre-Market Session

Medicinova Inc (MNOV) is up Friday morning, with the stock adding 5.41% in pre-market trading to 1.56. MNOV's short-term technical score of 9 indicates that the stock has traded less bullishly over the last month than 91% of stocks on the market. In the Biotechnology industry, which ranks 126 out of 146 industries, MNOV ra

Should You Hold Medicinova Inc (MNOV) Stock Friday Morning?

Medicinova Inc (MNOV) is down Tuesday morning, with the stock losing -5.15% in pre-market trading to 1.29. MNOV's short-term technical score of 2 indicates that the stock has traded less bullishly over the last month than 98% of stocks on the market. In the Biotechnology industry, which ranks 104 out of 146 industries, Med

Should You Hold Medicinova Inc (MNOV) Stock Tuesday Morning?

Medicinova Inc (MNOV) is up Wednesday morning, with the stock gaining 11.03% in pre-market trading to 1.51. MNOV's short-term technical score of 0 indicates that the stock has traded less bullishly over the last month than 100% of stocks on the market. In the Biotechnology industry, which ranks 100 out of 146 industries, M

Should You Sell Medicinova Inc (MNOV) Stock Wednesday Morning?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news!



We&rsquo;re seeing lots of earnings reports and acquisition deals moving stocks this morning.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MariaDB (NYSE:<a href="https://investorplace.com/stock-quotes/mrdb-stock-quote/">MRDB</a>) stock is rocketing 88% higher after Progress Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/prgs-stock-quote/">PRGS</a>) confirmed its <a href="https://www.globenewswire.com/news-release/2024/03/26/2852748/0/en/Progress-Software-Corp-Statement-regarding-Possible-Offer-for-MariaDB-plc.html">considering an offer for the company</a>.</li>



<li>Destiny Tech100 (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/">DXYZ</a>) shares are soaring more than 51% <a href="https://finance.yahoo.com/news/destiny-tech100-dxyz-list-york-130000099.html">after going public yesterday</a>.</li>



<li>PaySign (NASDAQ:<a href="https://investorplace.com/stock-quotes/pays-stock-quote/">PAYS</a>) stock is surging close to 24% after <a href="https://www.nasdaq.com/articles/paysign-q4-results-top-estimates-stock-up">beating Q4 estimates</a>.</li>



<li>Hitek Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/hkit-stock-quote/">HKIT</a>) shares are gaining over 19% without any clear news this morning.</li>



<li>The One Group Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/stks-stock-quote/">STKS</a>) stock is increasing more than 14% on news of <a href="https://www.nasdaq.com/press-release/the-one-group-hospitality-inc.-to-acquire-owner-of-benihana-2024-03-26">an acquisition deal</a>.</li>



<li>Ncino (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncno-stock-quote/">NCNO</a>) shares are rising over 14% after releasing <a href="https://finance.yahoo.com/news/ncino-inc-ncno-posts-strong-213133132.html">strong 2024 earnings</a>.</li>



<li>Trump Media &amp; Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/djt-stock-quote/">DJT</a>) stock is climbing more than 13% following its <a href="https://www.cnbc.com/2024/03/26/trump-media-stock-ticker-djt-debuts-after-dwac-merger.html">public debut yesterday</a>.</li>



<li>Nuvation Bio (NYSE:<a href="https://investorplace.com/stock-quotes/nuvb-stock-quote/">NUVB</a>) shares are heading over 12% higher after <a href="https://finance.yahoo.com/news/nuvation-bio-acquire-anheart-therapeutics-110000998.html">announcing an acquisition deal</a>.</li>



<li>Cazoo (NYSE:<a href="https://investorplace.com/stock-quotes/czoo-stock-quote/">CZOO</a>) stock is jumping more than 11% this morning.</li>



<li>MediciNova (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnov-stock-quote/">MNOV</a>) shares are up over 11% after <a href="https://www.nasdaq.com/press-release/medicinova-receives-a-notice-of-allowance-for-a-new-patent-covering-mn-166-ibudilast">getting a new patent</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Direct Digital (NASDAQ:<a href="https://investorplace.com/stock-quotes/drct-stock-quote/">DRCT</a>) stock is plummeting more than 42% after <a href="https://www.nasdaq.com/press-release/direct-digital-holdings-reports-q4-full-year-2023-results-2024-03-26">missing estimates in Q4 2023</a>.</li>



<li>Velo3D (NYSE:<a href="https://investorplace.com/stock-quotes/vld-stock-quote/">VLD</a>) shares are diving over 30% with the release of its <a href="https://finance.yahoo.com/news/velo3d-announces-fourth-quarter-fiscal-200500348.html">latest earnings report</a>.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) stock is taking a more than 20% beating after <a href="https://www.barrons.com/articles/gamestop-earnings-stock-price-489eef2e">posting an earnings miss</a>.</li>



<li>Akili (NASDAQ:<a href="https://investorplace.com/stock-quotes/akli-stock-quote/">AKLI</a>) shares are sliding over 19% despite a lack of news this morning.</li>



<li>Joann (NASDAQ:<a href="https://investorplace.com/stock-quotes/joan-stock-quote/">JOAN</a>) stock is tumbling more than 19% <a href="https://investorplace.com/2024/03/dear-joan-stock-fans-brace-for-a-suspension-on-march-28/">ahead of its stock suspension</a>.</li>



<li>LuxUrban Hotels (NASDAQ:<a href="https://investorplace.com/stock-quotes/luxh-stock-quote/">LUXH</a>) shares are decreasing over 13% after <a href="https://finance.yahoo.com/news/luxurban-hotels-inc-provides-preliminary-212900865.html">releasing Q4 results</a>.</li>



<li>Quhuo (NASDAQ:<a href="https://investorplace.com/stock-quotes/qh-stock-quote/">QH</a>) stock is declining more than 13% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318185982&amp;type=PDF&amp;symbol=QH&amp;cdn=74020f560df9ce8a2a4a9de29c3572f6&amp;companyName=Quhuo+Limited&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-03-26">new used-car trading platform</a>.</li>



<li>Mira Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/mira-stock-quote/">MIRA</a>) shares are slipping over 13% this morning.</li>



<li>Forge Global (NYSE:<a href="https://investorplace.com/stock-quotes/frge-stock-quote/">FRGE</a>) stock is dipping more than 12% on <a href="https://www.marketwatch.com/story/forge-global-shares-sink-after-lower-than-expected-4q-sales-4a3d009d">lagging Q4 sales</a>.</li>



<li>Rubicon Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/rbt-stock-quote/">RBT</a>) shares close out our pre-market stock movers down over 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/03/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-march-27th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Medicinova (MNOV) has shared an announcement. Geoffrey O'Brien will retire and step down from his role as Vice President at MediciNova, Inc. on Apr...

MediciNova Vice President Geoffrey O'Brien Announces Retirement

MediciNova anti-inflammatory drug gets issue notification for new patent

MediciNova anti-inflammatory drug gets issue notification for new patent, shares up

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MediciNova (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnov-stock-quote/">MNOV</a>) just reported results for the first quarter of 2024.<ul><li>MediciNova reported earnings per share of -6 cents. This was below the analyst estimate for EPS of -5 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/mnov-stock-earnings-medicinova-for-q1-of-2024/">MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MediciNova (NASDAQ:<a href="https://investorplace.com/stock-quotes/mnov-stock-quote/">MNOV</a>) just reported results for the second quarter of 2024.<ul><li>MediciNova reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -6 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/mnov-stock-earnings-medicinova-for-q2-of-2024/">MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

MNOV Stock Earnings: MediciNova Beats EPS for Q2 2024

MediciNova gains after patent win for long COVID therapy

CZOO

Legal

Press Releases

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

Analyst Ratings

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Management

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Comments

MediciNova

Noticias

Últimas noticias sobre MediciNova (NASDAQ:MNOV) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL